The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.

Cancer cells frequently show high constitutive activity of the antiapoptotic transcription factor nuclear factor kappaB (NF-kappaB), which results in their enhanced survival. Activation of NF-kappaB classically depends on degradation of its inhibitor IkappaBalpha by the 26s proteasome. Specific proteasome inhibitors induce apoptosis in cancer cells and, at nonlethal concentrations, sensitize cells to the cytotoxic effects of ionizing radiation and chemotherapeutic drugs. Recently, the protease coded by the HIV-I virus has been shown to share cleavage activities with the proteasome. For this reason, we investigated whether the HIV-I protease inhibitor saquinavir can inhibit NF-kappaB activation, block 26s proteasome activity in prostate cancer cells, and promote their apoptosis. The effect of saquinavir on LPS/IFN-gamma-induced activation of NF-kappaB was assessed by gel-shift assays and by Western analysis of corresponding IkappaBalpha-levels. Its effect on 20s and 26s proteasome activity was analyzed with a fluorogenic peptide assay using whole cell lysates from LnCaP, DU-145, and PC-3 prostate cancer cells pretreated with saquinavir for 9 h. Proteasome inhibition in living cells was assessed using ECV 304 cells stably transfected with an expression plasmid for an ubiquitin/green fluorescence protein fusion protein (ECV 304/10). Apoptosis was monitored morphologically and by flow cytometry. Saquinavir treatment prevented LPS/IFN-gamma-induced activation of NF-kappaB in RAW cells and stabilized expression of IkappaBalpha. It inhibited 20s and 26s proteasome activity in lysates from LnCaP, DU-145, and PC-3 prostate cancer cells with an IC(50) of 10 micro M and caused the accumulation of an ubiquitin/green fluorescence protein fusion protein in living ECV 304/10 cells. Incubation of PC-3 and DU-145 prostate cancer, U373 glioblastoma, and K562 and Jurkat leukemia cells with saquinavir caused a concentration-dependent induction of apoptosis. In the case of PC-3 and DU-145, saquinavir sensitized the surviving cells to ionizing radiation. We conclude that saquinavir inhibits proteasome activity in mammalian cells as well as acting on the HIV-I protease. Because saquinavir induced apoptosis in human cancer cells, HIV-I protease inhibitors might become a new class of cytotoxic drugs, alone or in combination with radiation or chemotherapy.

[1]  W. McBride,et al.  Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. , 2000, International journal of radiation oncology, biology, physics.

[2]  W. McBride,et al.  The Proteasome in Cancer Biology and Treatment , 2001, Radiation research.

[3]  K. Shinohara,et al.  Apoptosis induction resulting from proteasome inhibition. , 1996, The Biochemical journal.

[4]  C. N. Coleman,et al.  Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen , 1999, Oncogene.

[5]  F. Vittimberga,et al.  Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells. , 1999, Surgery.

[6]  A. Goldberg,et al.  Selective Inhibitors of the Proteasome-dependent and Vacuolar Pathways of Protein Degradation in Saccharomyces cerevisiae * , 1996, The Journal of Biological Chemistry.

[7]  M. Pagano,et al.  The ubiquitin-mediated proteolytic pathway as a therapeutic area , 1997, Journal of Molecular Medicine.

[8]  P. Volberding,et al.  HIV-1 protease inhibitors , 1992 .

[9]  D. Thomas,et al.  Permanent occupancy of the human immunodeficiency virus type 1 enhancer by NF-kappa B is needed for persistent viral replication in monocytes , 1996, Journal of virology.

[10]  T. McDonnell,et al.  Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53 , 1998, Oncogene.

[11]  C. Chen,et al.  Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells. , 1999, The Biochemical journal.

[12]  David Baltimore,et al.  NF-κB: Ten Years After , 1996, Cell.

[13]  M. Reitz,et al.  Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. , 2002, Blood.

[14]  Nanxin Li,et al.  Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H. Stellbrink,et al.  Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery , 2001, AIDS.

[16]  P. Elliott,et al.  Proteasome Inhibition: a New Strategy in Cancer Treatment , 2000, Investigational New Drugs.

[17]  Andrew Carr,et al.  HIV protease inhibitors , 1996, AIDS.

[18]  M. Bogyo,et al.  How an Inhibitor of the HIV-I Protease Modulates Proteasome Activity* , 1999, The Journal of Biological Chemistry.

[19]  M. Kurowski,et al.  Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir. , 1999, European journal of medical research.

[20]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[21]  C. Beglinger,et al.  HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. , 1999, Biochemical pharmacology.

[22]  L. Dick,et al.  Kinetic characterization of the chymotryptic activity of the 20S proteasome. , 1996, Biochemistry.

[23]  Aaron Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway , 1994, Cell.

[24]  M. Falchi,et al.  HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma , 2002, Nature Medicine.

[25]  S. Ōmura,et al.  Proteasome inhibitors induce mitochondria‐independent apoptosis in human glioma cells , 1999, FEBS letters.

[26]  M. Bogyo,et al.  A proteolytic system that compensates for loss of proteasome function , 1998, Nature.

[27]  P. Elliott,et al.  Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. , 2001, International journal of radiation oncology, biology, physics.

[28]  Q. Dou,et al.  Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts , 1998, Cell Death and Differentiation.

[29]  K. Lindsten,et al.  Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells , 2000, Nature Biotechnology.

[30]  C. Pellet,et al.  Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV‐related Kaposi's sarcoma , 1998, AIDS.

[31]  T. Thalhammer,et al.  Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. , 1993, The Journal of urology.

[32]  B. Dörken,et al.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.

[33]  R. Herbst,et al.  The proteasome inhibitor PS-341 in cancer therapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  D. Middlemas,et al.  Human Immunodeficiency Virus Protease Inhibitors Serve as Substrates for Multidrug Transporter Proteins MDR1 and MRP1 but Retain Antiviral Efficacy in Cell Lines Expressing These Transporters , 1998, Antimicrobial Agents and Chemotherapy.

[35]  I. Pastan,et al.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. , 1998, Biochemistry.

[36]  W. McBride,et al.  Inhibition of NF-κB, Clonogenicity, and Radiosensitivity of Human Cancer Cells , 1999 .